Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer

Competing Interest Statement

The study was supported by Daiichi Sankyo Taiwan Ltd. MS-C has received grant funding from NIH (grant number NIH-NHLBI R01HL130539). All authors have nothing else to be disclosed.

Clinical Trial

N/A

Funding Statement

The study was supported by Daiichi Sankyo Taiwan Ltd and NIH-NHLBI R01HL130539 (to MS-C).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study complied with the Declaration of Helsinki, with ethical approval from the Institutional Research Ethics Committee of Kaohsiung Medical University Hospital (IRB Number: KMUHIRB-EXEMPT(II)-21090039)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes